Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

Core Insights - Biomea Fusion, Inc. has received approval from the World Health Organization (WHO) for "icovamenib" as the International Nonproprietary Name (INN) for its lead product candidate BMF-219, which has also been adopted as the United States Adopted Name (USAN) [1][2] Company Overview - Biomea Fusion is a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules aimed at treating diabetes, obesity, and genetically defined cancers [3] - The company utilizes its proprietary FUSION™ System to discover and develop next-generation covalent-binding small molecule medicines, which are designed to provide greater target selectivity and lower drug exposure compared to conventional non-covalent drugs [3] Product Development - The suffix '-menib' in "icovamenib" indicates that it is a menin inhibitor, which is relevant to its therapeutic applications [1] - Biomea plans to use "icovamenib" in future presentations and publications as it advances the clinical development of this product candidate [2]